PoeweWStankovicIHallidayGMeissnerWGWenningGKPellecchiaMTet al
Enhanced Efficacy with Dual-Action Medications: Newer agents like tirzepatide, which target both GLP-1 and GIP receptors, have often demonstrated superior blood sugar lowering and more significant weight loss in clinical trials compared to GLP-1 RAs that only target one receptor
The 2024 NICE guideline NG239 covers these groups in detail
Proliferative diabetic retinopathy was numerically more common in the group with a rapid decline compared to the other groups (rapid 38% vs intermediate 17% and slow 17%) but the difference was not statistically significant (p=0.22)
In rare cases, Ozempic can cause gastroparesis, a serious condition that leads to pain, bloating, nausea, and vomiting
Patients receive realistic treatment plans, clear pricing, and long-term guidance